Novel oral chemotherapy agents.

被引：4

作者：

Royce M.E. ^{[1
]}

Hoff P.M. ^{[1
]}

Pazdur R. ^{[1
]}

机构：

[1] Department of Gastrointestinal Oncology and Digestive Diseases, The University of Texas MD Anderson Cancer Center, Box 78, 1515 Holcombe Boulevard, Houston, 77030, TX

来源：

Current Oncology Reports | 2000年 / 2卷 / 1期

关键词：

Clin Oncol; Irinotecan; Capecitabine; Temozolomide; Thymidine Phosphorylase;

D O I：

10.1007/s11912-000-0008-x

中图分类号：

学科分类号：

摘要：

The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens. Recently, interest in oral administration of chemotherapy has been stimulated by the discovery of oral fluoropyrimidines, which appear to possess at least an equivalent efficacy and the potential to reduce toxicity compared with intravenous therapies. Using rational drug design, several oral fluoropyrimidines have been developed, including capecitabine, UFT (tegafur and uracil), eniluracil plus oral 5-fluorouracil (5-FU), and S-1. In addition to the oral fluoropyrimidines, other novel agents available for potential oral administration include irinotecan and temozolomide.

引用

页码：31 / 37

页数：6

共 196 条

[1]

Murad A(1997)A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America Oncology 11 128-135

[2]

De Andrade C(1997)Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 110-115

[3]

Delfino C(1998)Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 301-308

[4]

Liu G(1998)The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology Oncology 12 23-27

[5]

Franssen E(1980)Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine Eur J Cancer 16 427-432

[6]

Fitch M(1993)Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer Eur J Cancer 29A 1658-1663

[7]

Diasio RB(1995)Metastatic colorectal cancer: advances in biochemical modulation and new drug development Semin Oncol 22 509-524

[8]

Bollag W(1990)Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy-5-fluorocytidine Jpn J Cancer Res 81 188-195

[9]

Hartmann H(1998)Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274-1281

[10]

Bajetta E(1998)Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts Biochem Pharmacol 55 1091-1097

← 1 2 3 4 5 6 7 8 9 10 →